- In October 2024, SK Pharmteco revealed plans to enhance its small molecule and peptide manufacturing capabilities with an investment of approximately USD 260 million in South Korea. This strategic investment is expected to strengthen SK Pharmteco's position in the global small molecule API market by expanding its production capacity and supporting growing demand for both small molecule and peptide APIs
- In July 2024, Ventus Therapeutics announced the opening of a new office and laboratory in Montreal, Canada, marking a significant expansion of its R&D capabilities. This move is poised to boost the company's innovation potential in the small molecule API sector, particularly in the development of novel therapies, contributing to the overall growth of the market
- In June 2024, Matrix Pharma acquired the API business of Viatris Inc., with funding provided by KSSF II. This acquisition is expected to enhance Matrix Pharma's market share and competitiveness in the Indian API market, as it significantly expands its portfolio and strengthens its production capabilities in one of the fastest-growing regions for small molecule APIs
